A

Agilent Technologies
D

A

Arincen80/100B

If you had invested in Agilent Technologies ago, it would be worth $4,032 today, against $4,096 in SPY and $6,368 in QQQ.

ArincenArincen ScoreBeta

80/100

Six parts of the company, five checks each, from its own reported figures. A part scores the checks it passes out of 10; the score is their average out of 100.

Profitability6

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Cash10

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Valuation6

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Growth10

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Financial strength8

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Shareholders8

Plus shows the checks behind each part of the score, what passed, what failed and the figure it read, for every stock.

Figures to FY2025; the price as of today.

Agilent Technologies key facts

Style
Blend stock · 4.7/10Growth 4.1 · Value 4.7 · Dividend 2.4
Day range
170.960 – 173.895
52-week range
108.350 – 182.990
Market capitalization
48.20B USD
P/E
33.59
PEG ratio
1.92
EPS
5.09
Div Yield
0.60%
EPS growth forecast (FY2026)
+11.1%
Volume
2,245
Beta
1.24
ESG score
70.0/100Environment 77 · Social 70 · Governance 63
Sector
Healthcare
Industry
Medical - Diagnostics & Research
CEO
Padraig McDonnell
Employees
18K
IPO date
18 Nov 1999

Agilent Technologies earnings

Next earnings · Q4 FY2026
EPS estimate
1.73 USD
Revenue estimate
1.99B USD
Last quarter · Q3 FY2026
EPS1.62Beat +8.7%Revenue1.88BBeat +2.0%

Revenue

ReportedEstimate

EPS

ReportedEstimate
PeriodReport dateEPS estimateReported EPSSurpriseEPS growthRevenue estimateReported revenueSurpriseRevenue growth
Q1 FY20281.64——+9.29%2.04B——+5.72%
Q2 FY20271.60——+7.70%1.96B——+6.82%
Q1 FY20271.50——+10.00%1.92B——+7.06%
Q4 FY20261.73——+8.81%1.99B——+8.15%
Q3 FY20261.491.62+8.72%+18.25%1.84B1.88B+1.98%+8.06%
Q2 FY20261.411.49+5.67%+13.74%1.80B1.84B+2.03%+10.01%
Q1 FY20261.371.36-0.73%+3.82%1.81B1.80B-0.54%+6.96%
Q4 FY20251.581.59+0.36%+8.90%1.83B1.84B+0.36%+8.11%
Q3 FY20251.371.370.00%+3.79%1.68B1.74B+3.17%+10.14%
Q2 FY20251.261.31+3.97%+7.38%1.63B1.67B+2.54%+6.04%

Analysts' estimates for FY2026 over the last 7 days:EPS Revenue How the estimates moved

Agilent Technologies analyst forecast

12-month price target
174.29 USD
+1.95%

Analysts' 1-year price targets range from 150.00 to 195.00, with an average of 174.29.

Past year
1-year forecast
Strong sellStrong buy
Strong buy
17 ratings
Buy
15
Hold
2
Sell
0

12-month price target

Highest target195.00
Average target174.29
Lowest target150.00
Current price170.96

Agilent Technologies valuation

Price to earnings ratio (TTM)
33.59
Forward P/E (FY2027)
25.52
Price to sales (TTM)
6.54
Price to book
6.55
EV / EBITDA (TTM)
24.76

Capital structure

Market capitalization
48.20B USD
+
Total debt
3.95B USD
−
Cash and short-term investments
1.76B USD
=
Enterprise value
50.40B USD

Valuation over time

P/EForward P/EForward P/E · EstimateEstimate
Fiscal yearP/EForward P/EP/SP/BEV/EBITDA
FY2028 (est.)23.05————
FY2027 (est.)25.5223.05———
FY2026 (est.)27.5725.52———
Now (TTM)33.5925.426.546.5524.76
FY202531.8923.605.966.1423.43
FY202429.3523.385.806.4121.36
FY202324.5025.364.455.2018.52
FY202233.0231.136.047.8022.62
FY202139.4631.087.568.8627.80

Agilent Technologies against its own history

Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.

Its peers: Natera, Waters, IDEXX Laboratories, IQVIA Holdings, Mettler-Toledo International, and Illumina, the US Medical - Diagnostics & Research companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.

  • P/E (today)Above its median33.6
    22.750.7
  • Gross marginBelow its median52.4%
    50.7%54.4%
    Against its peers: 6 of 7Peers' median 60.6%
  • Operating marginBelow its median21.3%
    19.8%23.6%
    Against its peers: 4 of 7Peers' median 23.8%
  • Net marginAt its median18.8%
    18.1%19.8%
    Against its peers: 5 of 7Peers' median 19.9%
  • Return on equityLowest in 5 years19.3%
    19.3%23.6%
    Against its peers: 5 of 6Peers' median 25.1%
  • Free cash flow marginBelow its median16.6%
    14.9%21.6%
    Against its peers: 5 of 7Peers' median 19.1%
  • Revenue growthAt its median6.7%
    -4.7%18.4%
    Against its peers: 4 of 7Peers' median 6.4%
  • EPS growthBelow its median3.2%
    0.2%71.3%
    Against its peers: 4 of 5Peers' median 4.3%
  • Debt to EBITDAAbove its median1.83×
    1.45×1.91×
    Against its peers: 4 of 6Peers' median 1.75×
  • Current ratioLowest in 5 years1.96
    1.962.61
    Against its peers: 3 of 7Peers' median 1.45

Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.

Agilent Technologies growth and profitability

Revenue (TTM)
7.37B USD
Net income (TTM)
1.44B USD
Gross margin
53.73%
Operating margin
22.23%
Net margin
19.53%

Revenue / Net income

Revenue Net income Net margin
PeriodRevenueGrowthNet incomeGrowthGross marginOperating marginNet marginEBITDAGrowth
FY20256.95B+6.73%1.30B+1.09%52.43%21.29%18.75%1.84B-2.08%
FY20246.51B-4.73%1.29B+3.95%54.30%22.86%19.80%1.87B+10.04%
FY20236.83B-0.22%1.24B-1.12%50.71%19.76%18.15%1.70B-10.60%
FY20226.85B+8.37%1.25B+3.64%54.35%23.63%18.31%1.91B+8.12%
FY20216.32B+18.36%1.21B+68.29%53.92%21.32%19.15%1.76B+43.49%

Agilent Technologies revenue breakdown

By product

FY2025
Agilent CrossLab: 41.9%Life Sciences and Applied Markets: 39.2%Applied Markets: 18.9%41.9%Agilent CrossLab39.2%Life Sciences and Applied Markets18.9%Applied Markets
SegmentRevenueShare of revenueChange on the year
Agilent CrossLab2.91B41.9%+76.9%
Life Sciences and Applied Markets2.73B39.2%-15.2%
Applied Markets1.31B18.9%—

By region

FY2025
Americas: 40.4%Asia Pacific: 31.9%Europe: 27.7%40.4%Americas31.9%Asia Pacific27.7%Europe
RegionRevenueShare of revenueChange on the year
Americas2.81B40.4%+9.1%
Asia Pacific2.22B31.9%+2.4%
Europe1.92B27.7%+8.6%

How Agilent Technologies makes its money

Agilent CrossLab2.91B 41.9%
Life Sciences and Applied Markets2.73B 39.2%
Applied Markets1.31B 18.9%
Revenue6.95B 100.0%
Cost of revenue3.31B 47.6%
Gross profit3.64B 52.4%
Research and development455.00M 6.5%
Selling and administration1.71B 24.6%
Operating income1.48B 21.3%
Tax132.00M 1.9%
Other expense44.00M 0.6%
Net income1.30B 18.8%

FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.

Agilent Technologies dividends

Annual dividend
1.02 USD
Dividend yield (indicated)
0.60%
Payout ratio
20.04%
Years of dividend growth
14
Frequency
Quarterly
Last payment
0.26 USD
Last ex-dividend date
6 Oct 2026
Last payment date
28 Oct 2026

Dividends per share

Year2025202420232022202120202019201820172016
Dividends per share0.990.940.900.840.780.720.660.600.530.46

Agilent Technologies financial health

Cash and short-term investments
1.76B USD
Total debt
3.95B USD
Net cash
-2.19B USD
Free cash flow (TTM)
1.27B USD
Current ratio
2.05
Debt to equity
0.54
Piotroski score
6 / 9
Altman Z-score
5.74

Cash, debt and free cash flow

Cash and short-term investments Total debt Free cash flow
Fiscal yearCash and short-term investmentsTotal debtFree cash flow
FY20251.79B3.35B1.15B
FY20241.33B3.57B1.37B
FY20231.59B2.74B1.47B
FY20221.05B2.77B1.02B
FY20211.58B2.73B1.30B

Agilent Technologies ownership

Institutions
93.26%
Institutional holders
1,168 (+57)
Free float
99.67%

Who owns the shares

Institutions 93.3% Others 6.7%
As of 30 Jun 2026

Shares free to trade

Free float 281.04M shares ·99.7% Closely held 929.68K shares ·0.3%

Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.

Insider trading

QuarterPurchasesSalesShares acquiredShares disposed of
Q3 202601817.00634.00
Q2 2026018.87K2.42K
Q1 20260023.53K1.94K
Q4 202504111.31K43.44K

Shares outstanding

Basic shares Diluted shares Change in diluted shares
Fiscal yearBasic sharesDiluted sharesChange in diluted shares
FY2025283.00M284.00M-2.41%
FY2024290.00M291.00M-1.69%
FY2023294.00M296.00M-1.33%
FY2022299.00M300.00M-2.28%
FY2021304.00M307.00M-1.60%

Source: Financial Modeling PrepVerified against SEC filings

Signals
buy
A
AAgilent Technologies @144.68
2025-11-04 04:07
A@144.68 Chart
Profit
393.50
USD
5.44%
More
Related Instruments

Title: Agilent Technologies

Sector: Healthcare
Industry: Medical - Diagnostics & Research
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest countryconcentrations.

Common questions about Agilent Technologies stock